Jumping to Kala

Quote












anonymous said:
go to Kala, Same story different playground. Reformulation, specialty pharmacy, no coverage. steroids have been around forever[/QUOT

Maybe, but Sun is really no better. I think many people are just tired of the leadership team here. Let’s face facts, they are not very good. Some of the RSM team is a group of turds. Combine that with big salary offers and you understand why.
Click to expand...
 






Maybe you are correct. Maybe some are just tired of the leadership team. The RSM team is a real collection of turds. Combine that with big base salary offers and you get why.
 
























anonymous said:
Go soft. You probably will be asking to come back in a month or two.
Click to expand...
All this is an affirmation that Sun can only get the bottom of the pharma barrel or the top of those coming out of Appliance sales at Best Buy.
Anyone worth their salt can easily ‘get the skinny’ on the real deal.
Massive turnover, sketchy people, complete failure in the US. If you need short-term, mediocre healthcare coverage for your family, then take their offer, and keep looking.
It’s a common theme here.
 












anonymous said:
Kala product will be a bigger product than xiidra and push 1 billion in sales. According to their market research. Game changer.
Click to expand...

Ophth companies always make sweeping claims and promises that they cannot keep. More expensive, lame, so-called technology that addresses common symptoms and requires life-long treatment. Managed care will be tough and not roll on this too quick. Your same profound excuses for not being able to pull-through SUN products will ring large yet again at Kala. Keep moving from company to company until the lottery number hits.
 






anonymous said:
Ophth companies always make sweeping claims and promises that they cannot keep. More expensive, lame, so-called technology that addresses common symptoms and requires life-long treatment. Managed care will be tough and not roll on this too quick. Your same profound excuses for not being able to pull-through SUN products will ring large yet again at Kala. Keep moving from company to company until the lottery number hits.
Click to expand...
Same BS different day. And how do you all really think it’s going to go when an office has to do a PA for a TWO week course of therapy?!? Not gonna happen unless you go through a speciality pharmacy and then you’re risking your ass compliance wise. And the samples will be enough so if you sample much there won’t be many Rxs. Not to mention Inveltys sucks! The grass is not always greener.
 


















anonymous said:
Their product is going to be a game changer.
Click to expand...


Try looking at their “research” and projections for Inveltys...........not anything near accurate—-most areas of the Nation don’t even have 1% share!!!. Same people are making the same projections for their dry eye product. It too will be a laughable failure.
 


















I will point out that though loteprednol is not new, the indication is distinct and the product will be the only one in its class.

There is an army of several more cyclosporine products in the dry eye market pipeline, as well as many novel molecules. I want you to consider the long term viability of Cequa should market access fail on their end, and a generic Restasis comes to market. The dry eye landscape will soon resemble that of glaucoma, and all companies will be vying to be the formulary king.

I would be hoping that Sun acquires and launches a new high revenue potential product in the next year or two...
 






anonymous said:
I will point out that though loteprednol is not new, the indication is distinct and the product will be the only one in its class.

There is an army of several more cyclosporine products in the dry eye market pipeline, as well as many novel molecules. I want you to consider the long term viability of Cequa should market access fail on their end, and a generic Restasis comes to market. The dry eye landscape will soon resemble that of glaucoma, and all companies will be vying to be the formulary king.

I would be hoping that Sun acquires and launches a new high revenue potential product in the next year or two...
Click to expand...
 






anonymous said:
I will point out that though loteprednol is not new, the indication is distinct and the product will be the only one in its class.

There is an army of several more cyclosporine products in the dry eye market pipeline, as well as many novel molecules. I want you to consider the long term viability of Cequa should market access fail on their end, and a generic Restasis comes to market. The dry eye landscape will soon resemble that of glaucoma, and all companies will be vying to be the formulary king.

I would be hoping that Sun acquires and launches a new high revenue potential product in the next year or two...
Click to expand...

You’re delusional.
Companies that “acquire and launch new high revenue potential products” as you say, are sales and marketing machines.

Sun is neither.

Sun is all about cost, thus its why it produces so much generic business. A completely different strategic capability is needed to succeed in large therapeutic, branded business.

Dilip has lost nearly $10B of net worth the past few years. The markets - both healthcare and financial, have given Sun the thumbs-down.

Stick to punching out low-cost generic pills.
 












Top Bottom
Back
Quote